{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:59:20Z","timestamp":1793055560081,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacadv.2026.102821","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:24:38Z","timestamp":1781724278000},"page":"102821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P2","title":["Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax"],"prefix":"10.1016","volume":"5","author":[{"given":"Sabin","family":"Filimon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azin","family":"Ghamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azin","family":"Vakilpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Achar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M.","family":"DeCara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Altman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1030-8119","authenticated-orcid":false,"given":"Kyle A.","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah K.","family":"Gilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5916-717X","authenticated-orcid":false,"given":"Deep","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Chittams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Anazco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Scherrer-Crosbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.102821_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102821_bib2","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy-ineligible and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jacadv.2026.102821_bib3","first-page":"2777","article-title":"Determining risk factors associated with cardiovascular complications in patients with acute leukemia","volume":"17","author":"Abasi","year":"2025","journal-title":"A Systematic Review"},{"key":"10.1016\/j.jacadv.2026.102821_bib4","article-title":"Decitabine-induced delayed cardiomyopathy in hematologic malignancy","volume":"2018","author":"Agasthi","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.jacadv.2026.102821_bib5","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41409-019-0536-y","article-title":"Prophylactic azacitidine and donor lymphocyte infusions after allogeneic transplant for high-risk AML and MDS: a phase II study","volume":"54","author":"Guillaume","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.102821_bib6","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2008.17.1058","article-title":"Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes","volume":"27","author":"Lyons","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacadv.2026.102821_bib7","first-page":"1923","article-title":"Cardiac failure in patients treated with azacitidine: case reports and vigibase disproportionality analysis","volume":"88","author":"Perino","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacadv.2026.102821_bib8","first-page":"1869","article-title":"Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"92","author":"Raza","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jacadv.2026.102821_bib9","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.2009.26.0745","article-title":"Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes","volume":"28","author":"Sekeres","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacadv.2026.102821_bib10","first-page":"373","article-title":"Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes","volume":"117","author":"Sekeres","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jacadv.2026.102821_bib11","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.3390\/ijms23116260","article-title":"Venetoclax induces cardiotoxicity via oxidative-stress-mediated inflammation and apoptosis through NF-\u03baB and BCL-2","volume":"23","author":"AlAsmari","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacadv.2026.102821_bib12","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1182\/bloodadvances.2022007333","article-title":"Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents","volume":"6","author":"Johnson","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacadv.2026.102821_bib13","first-page":"75","article-title":"Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines","volume":"10","author":"Onoue","year":"2024","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jacadv.2026.102821_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","article-title":"2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102821_bib15","series-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0","year":"2017"},{"key":"10.1016\/j.jacadv.2026.102821_bib16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102821_bib17","first-page":"747","article-title":"Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax plus hypomethylating agents","volume":"200","author":"Johnson","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacadv.2026.102821_bib18","first-page":"522","article-title":"Pericardial involvement in cancer","volume":"3","author":"Chahine","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.102821_bib19","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: the ATRIA study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2026.102821_bib20","first-page":"689","article-title":"Relation between cancer and atrial fibrillation: findings from the REGARDS study","volume":"2","author":"O'Neal","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.102821_bib21","first-page":"703","article-title":"Association of atrial fibrillation with cancer subtype: a SEER-based analysis","volume":"13","author":"Khan","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jacadv.2026.102821_bib22","first-page":"501","article-title":"Impact of atrial fibrillation on heart failure in patients treated with anthracycline chemotherapy","volume":"4","author":"Onoue","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.102821_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ahj.2012.03.020","article-title":"Prevalence of Takotsubo cardiomyopathy in the United States","volume":"164","author":"Deshmukh","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacadv.2026.102821_bib24","first-page":"127","article-title":"Stress-induced cardiomyopathy in cancer patients","volume":"2","author":"Giza","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.102821_bib25","first-page":"e10","article-title":"Takotsubo cardiomyopathy in cancer patients","volume":"16","author":"Desai","year":"2021","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.jacadv.2026.102821_bib26","first-page":"1553","article-title":"Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America","volume":"28","author":"Bloom","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacadv.2026.102821_bib27","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/blood-2011-06-358226","article-title":"Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation","volume":"118","author":"Armenian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.102821_bib28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102821_bib29","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102821_bib30","first-page":"909","article-title":"Impact of early discontinuation and dose modification of venetoclax on outcomes in relapsed\/refractory CLL: post hoc MURANO study analyses","volume":"107","author":"Mato","year":"2022","journal-title":"Haematologica"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26002425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26002425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:26:03Z","timestamp":1783725963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26002425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2772963X26002425"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102821","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102821"}}